Mechanism of action and high-level overview of clinical results

P. Shah (London, United Kingdom)

Source: Annual Congress 2013 –Introduction to endoscopic lung volume reduction with RePneu LVR coils
Session: Introduction to endoscopic lung volume reduction with RePneu LVR coils
Session type: Practical Workshop
Number: 2978

Slide presentation

Rating: 4
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Shah (London, United Kingdom). Mechanism of action and high-level overview of clinical results. Annual Congress 2013 –Introduction to endoscopic lung volume reduction with RePneu LVR coils

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Mechanism of action & high-level overview of clinical results
Source: International Congress 2014 – Hands-on practice with coils for treatment of advanced emphysema
Year: 2014

Clinical and translational research: an overview
Source: ERS Course 2015
Year: 2015

Characterisation of clinical phenotypes is mandatory for the development of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

Implications of the exposome and its applicability in clinical and epidemiological studies
Source: International Congress 2016 – Genetics, epigenetics and the exposome
Year: 2016

Clinical trial landscape for M/XDR-TB: current evidence and future perspectives
Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis
Year: 2019

Historical overview: On the evolution of respiratory support for neonates
Source: Research Seminar 2009 - The rationale and use of surfactant and continuous positive airway pressure (CPAP) in extremely low gestational age neonates (ELGANs)
Year: 2009

Pirfenidone: an update on clinical trial data and insights from everyday practice
Source: Eur Respir Rev 2014; 23: 111-117
Year: 2014

Respiratory monitoring: revisiting classical physiological principles with new tools
Source: Eur Respir J 2004; 24 : 718-719
Year: 2004

COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020

Late Breaking Abstract - Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study
Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension
Year: 2021

CPET overview: clinical usefulness and limitations
Source: ERS Skills course - Clinical exercise testing: advanced
Year: 2018

Translation of in vitro findings to patients with asthma: a timely and compelling challenge
Source: Eur Respir J, 54 (4) 1901759; 10.1183/13993003.01759-2019
Year: 2019

How to accelerate bringing new drugs to patients: role of clinical trials networks
Source: International Congress 2019 – Rare lung diseases
Year: 2019

General overview of system biology and network analysis
Source: ERS Research Seminar 2017 – Integrating systems biology approach in idiopathic pulmonary fibrosis research
Year: 2016

A critical evaluation of the relevance of different asthma phenotypes for clinical practice
Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium
Year: 2008